BioSpace News Archive

ClearPoint Neuro, Inc. today announced it has received 510(k) clearance for its Prism Bone Anchor Accessory.

Evox Therapeutics Ltd, a leading exosome therapeutics company, announces that Dr. Per Lundin, Co-Founder and Chief Business Officer, has been appointed as Chief Executive Officer of the Company and will be appointed to its Board of Directors.

selectION, Inc., a clinical-stage biopharmaceutical company developing novel treatments for T-cell mediated autoimmune diseases, announced positive results from the first-in-human Phase 1b trial of its lead compound, si-544, in atopic dermatitis patients.

MiLaboratories, a leader in RNA immune technologies, and Miltenyi Biotec, a global pioneer in biotechnology, are excited to announce a landmark partnership that promises to revolutionize the field of next-generation therapies.

Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced that the company will host the Q1 Quarterly Results webcast tomorrow, April 30, at 10 a.m. CET.

Theravance Biopharma, Inc. will report its first quarter 2024 financial results and provide a business update after market close on Monday, May 13, 2024.

Asensus Surgical, Inc., a medical device company that is digitizing the interface between the surgeon and the patient, announced that Sendai Tokushukai Hospital in Japan has entered into an agreement to lease and utilize a Senhance® Surgical System.

Pfizer Inc. highlights its progress in advancing new potential standards of care in Oncology at the 2024 American Society of Clinical Oncology Annual Meeting, taking place May 31 to June 4 in Chicago.

4P-Pharma, a Lille-based clinical-stage startup studio focused on developing curative therapies for untreated serious diseases, announces that it has successfully secured a total capital of €15 million in its second closing with participation from private investors.

Positive topline results from the DESTINY-Breast06 phase 3 trial showed that ENHERTU® demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard of care chemotherapy in the primary trial population of patients with HR positive, HER2 low metastatic breast cancer following one or more lines of endocrine therapy.